Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

August 31, 2025

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor

"1. Azacytidine (75 mg/m2/day, days 1 to 7).~2. Cytarabine (75-100 mg/m2 bid, days 1 to 5).~3. Aclacinomycin(20 mg/day, days 1,3,5).~4. Chidamide (30 mg/day , days 1,4,8,11).~5. Venetoclax (400 mg/day, days 1 to 14,Combined with posaconazole reduced to 100 mg/day,Combined with voriconazole reduced to 200 mg/day ).~6. Granulocyte colony-stimulating factor (300 μg/day, day 0 until agranulocytosis recovery)"

DRUG

"3+7"

"IA regimen:~1. Idarubicin (8-10 mg/m2) for 3 days .~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days.~DA regimen:~1. Daunorubicin(60 mg/m2) for 3 days.~2. Cytarabine (75-100mg/m2, every 12 hrs) for 7 days."

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors
collaborator

940 Hospital of the People's Liberation Army Joint Logistic Support Force

OTHER

collaborator

The General Hospital of Western Theater Command

OTHER

collaborator

The General Hospital of Northern Theater Command

OTHER

collaborator

The 960th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army

UNKNOWN

collaborator

Air Force Military Medical University, China

OTHER

collaborator

Yantai Yuhuangding Hospital

OTHER

collaborator

People's Liberation Army (PLA) Strategic Support Force Characteristic Medical Center

UNKNOWN

collaborator

First Hospital of China Medical University

OTHER

lead

Chinese PLA General Hospital

OTHER